Pipeline

Developing Differentiated Biologic Therapies

ADAXION’s technology is designed to enable the development of novel biologic therapies that overcome immunogenicity limitations.

ADX-001: Bispecific Antibody Targeting TNFα and IL-23 for Inflammatory Disease

  • Reduced Immunogenicity: ADAx technology enables the development of a bispecific class that has historically exhibited prohibitive anti-drug antibodies (ADAs)
  • Enhanced Efficacy: Dual TNFα and IL-23 targeting with clinical precedence shown to drive additive clinical remission rates compared to monotherapies
  • Patient Convenience: Extended half-life design and amenable to subcutaneous dosing
  • Streamlined Development Path: Bispecific approach overcomes development challenges associated with co-formulations

ADX-004: Bispecific Antibody Targeting TL1A and IL-23 for Inflammatory Disease

  • Reduced Immunogenicity: ADAx technology enables the development of a bispecific class with expected prohibitive anti-drug antibodies (ADAs)
  • Enhanced Efficacy: Dual TL1A and IL-23 targeting intended to drive additive clinical remission rates compared to monotherapies
  • Patient Convenience: Extended half-life design and amenable to subcutaneous dosing
  • Streamlined Development Path: Bispecific approach overcomes development challenges associated with co-formulations

EndoS: IgG-Deactivating Enzyme for IgG-Driven Disease

  • Novel Mechanism: Inhibits FcγR binding and complement activation of IgG while maintaining antibody levels
  • Reduced Immunogenicity: ADAx technology is designed to enable the development of an otherwise immunogenic bacterial enzyme
  • Enhanced Efficacy: Fast-acting mechanism eliminates IgG effector function within hours
  • Patient Convenience: Catalytic activity enables potential for low dose treatment

IDE: IgG-Degrading Enzyme for IgG-Driven Disease

  • Reduced Immunogenicity: ADAx technology enables development of an immunogenic bacterial enzyme that has historically exhibited prohibitive ADAs
  • Enhanced efficacy: Potent enzymatic activity drives complete IgG cleavage within hours, rapidly eliminating Fc-mediated effector function with transient reduction of circulating IgG
  • Patient Convenience: Catalytic activity combined with half-life extension supports low dosing and infrequent administration with sustained pharmacodynamic effect
Scroll to Top